Acadia Pharmaceuticals

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops and commercializes therapies for underserved neurological disorders and rare diseases. Its FDA-approved medicines include NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome, with a pipeline addressing Alzheimer's disease psychosis.

Acadia Pharmaceuticals is a biopharmaceutical company focused on turning scientific promise into meaningful innovation for underserved neurological and rare disease communities. The company has developed and commercialized the first FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome, marketed as NUPLAZID and DAYBUE respectively.

Acadia's pipeline includes mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, as well as earlier-stage programs addressing other unmet patient needs. The company's therapeutic areas are centered on disorders where few or no approved therapies currently exist.

The company makes money through the sales of its approved medicines and invests in research and development to advance new therapies. Acadia operates across North America and Europe, with a focus on collaborating with patients, caregivers, and healthcare providers to guide innovation.